The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.

Joussen, Antonia M; Wolf, Sebastian; Kaiser, Peter K; Boyer, David; Schmelter, Thomas; Sandbrink, Rupert; Zeitz, Oliver; Deeg, Gesa; Richter, Annett; Zimmermann, Torsten; Hoechel, Joachim; Buetehorn, Ulf; Schmitt, Walter; Stemper, Brigitte; Boettger, Michael K (2019). The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial. British journal of clinical pharmacology, 85(2), pp. 347-355. Wiley-Blackwell 10.1111/bcp.13794

[img] Text
Joussen_et_al-2018-British_Journal_of_Clinical_Pharmacology.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (493kB) | Request a copy

AIMS This program investigated topical regorafenib, a multikinase inhibitor, in patients with neovascular age-related macular degeneration (nAMD). METHODS Topical regorafenib was investigated in an open-label, phase IIa/b study in which patients with choroidal neovascularization (CNV) secondary to nAMD received regorafenib (25 μL, 30 mg/mL TID) for 12 weeks. The primary endpoint of the phase II/a/b study was mean change in best-corrected visual acuity (BCVA) from baseline to weeks 4 and 12. RESULTS In nAMD patients (N = 51), mean changes in BCVA were +1.2 (90% CI -0.61 to 2.97) and -2.4 (90% CI, -4.18 to -0.54) letters at weeks 4 and 12, respectively. Ocular treatment-emergent adverse events (TEAEs) (study eye) were reported in 21 patients by week 12. There was 1 serious ocular TEAE (visual acuity reduced) that was not drug related. Twenty patients required rescue (intravitreal ranibizumab). CONCLUSIONS The program was terminated after phase IIa ended because efficacy was less than with current nAMD treatments. According to elaborate post hoc analyses, the most likely reason was insufficient exposure in the target compartment (back of the eye).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Wolf, Sebastian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0306-5251

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Sebastian Wolf

Date Deposited:

28 Nov 2018 13:10

Last Modified:

22 Jan 2019 01:32

Publisher DOI:

10.1111/bcp.13794

PubMed ID:

30341774

Uncontrolled Keywords:

Clinical Trials Drug Development Ophthalmology Pharmacometrics

BORIS DOI:

10.7892/boris.121538

URI:

https://boris.unibe.ch/id/eprint/121538

Actions (login required)

Edit item Edit item
Provide Feedback